psilocybin therapy

Kaya Holdings, Inc. (OTCQB:KAYS), a company engaged in the emerging psilocybin treatment sector and medical/recreational cannabis, has voiced strong criticism of the FDA’s decision to reject MDMA therapy as a treatment for post-traumatic stress disorder (PTSD). KAYS, which operates The Sacred...

Providers at Utah's two largest healthcare systems may now treat patients with psilocybin and MDMA as part of a pilot program created by a proposal-turned-law that will take effect as early as May 1, 2024.  The program, open to providers at the University of Utah Health and Intermountain Health,...

Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.)  With variable symptoms, the condition typically...

A protracted legal battle led by Dr. Sunil Aggarwal and the Advanced Integrative Medical Science Institute (AIMS) against the Drug Enforcement Administration (DEA) for the latter's refusal to allow psilocybin treatment for terminally-ill patients has taken another turn. Dr. Aggarwal's original...

Biopharma company Apex Labs Ltd. has completed one of the first take-home microdose psilocybin clinical trials, meeting all study endpoints over a two-month period with no adverse events reported. CEO Tyler Powell called it a clinical milestone and said he's certain it will help the...

Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF)’s Phase 1/2 clinical study assessing safety and efficacy of oral psilocybin for the treatment of Methamphetamine Use Disorder (MUD) has enrolled its first subject.  The investigator-initiated trial led by Dr. Christopher...

Ontario-based Red Light Holland Corp. (OTCQB: TRUFF) has committed to becoming an aligned supporter and advocate with the non-profit TheraPsil. The two entities are engaged in advancing a charter challenge relating to the prohibition of psilocybin under the Controlled Drugs and Substances Act (CDSA...

Apex Labs Ltd., an Iter Investment’s portfolio biopharma company developing psilocybin therapeutics, has been granted approval by Health Canada to begin its large take-home psilocybin clinical trial.  The randomized, double-blind, placebo-controlled Phase 2b study will evaluate the...

After a positive start of Virginia's 2023 state congressional session, one of the two projects seeking to legalize psychedelics in Virginia received a negative vote from a key House panel on Wednesday, January 18. Introduced on Jan. 4 by Del. Dawn Adams (D) to the Virginia General...

Missouri Rep. Tony Lovasco (R) recently laid out his plans to file a psychedelics bill providing therapeutic access to psilocybin for those suffering from serious mental health conditions, reported Marijuana Moment. The legislation constitutes a revision from a prior version Lovasco...

What a year for psychedelics! It feels like we’ve come a long way since the sector explode in 2019-2020, the launch of Benzinga's Psyched, companies’ massive migration from private to public, MAPS’ initiation of Phase 3 MDMA trials, the surge of the psilocybin wave,...

Following the November midterm results on local opt-outs, the Oregon Health Authority (OHA) announced it has adopted the final subset of rules “to regulate the production of psilocybin products and the provision of psilocybin services” -aka the Oregon Psilocybin Services Act,...

The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a No Objection letter and is set to proceed with the first-ever Phase 2a clinical trial on the magic...

The agency regulating all things related to psychedelic-assisted therapy (PAT), Health Canada released a notice to stakeholders on risk-management measures for clinical trials, a seemingly supporting move towards future government-supported access.  As stated, the purpose of notice 22-...

Canadian drug development company Diamond Therapeutics Inc. announced it has successfully completed its Phase 1 clinical study on low-dose psilocybin and shared the trial’s most relevant results.  The Toronto-based company is focused on sub-perceptual, non-hallucinogenic treatments that...